| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/12/2023 | 10.34% | Benchmark | → $19 | Reiterates | Buy → Buy |
| 05/08/2023 | 39.37% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2023 | 27.76% | Credit Suisse | → $22 | Reiterates | → Outperform |
| 02/23/2023 | 16.14% | BMO Capital | $15 → $20 | Maintains | Outperform |
| 02/23/2023 | 4.53% | Deutsche Bank | $17 → $18 | Maintains | Buy |
| 01/24/2023 | -1.28% | Deutsche Bank | $12.5 → $17 | Maintains | Buy |
| 12/01/2022 | 27.76% | Credit Suisse | $24 → $22 | Maintains | Outperform |
| 10/13/2022 | -12.89% | Goldman Sachs | $22 → $15 | Maintains | Buy |
| 07/29/2022 | 27.76% | Deutsche Bank | $25 → $22 | Maintains | Buy |
| 02/24/2022 | 50.99% | Benchmark | $24 → $26 | Maintains | Buy |
| 12/10/2021 | 21.95% | JP Morgan | $22 → $21 | Downgrades | Overweight → Neutral |
| 11/17/2021 | 39.37% | Wolfe Research | → $24 | Initiates Coverage On | → Outperform |
| 10/28/2021 | 39.37% | Credit Suisse | $26 → $24 | Maintains | Outperform |
| 09/10/2021 | 45.18% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 04/29/2021 | 33.57% | Credit Suisse | $19 → $23 | Maintains | Outperform |
| 04/23/2021 | 4.53% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 03/22/2021 | 21.95% | Northland Capital Markets | $14 → $21 | Upgrades | Market Perform → Outperform |
| 02/08/2021 | -24.51% | Northland Capital Markets | → $13 | Downgrades | Outperform → Market Perform |
| 12/17/2020 | 4.53% | BMO Capital | → $18 | Upgrades | Market Perform → Outperform |
| 04/30/2020 | -47.74% | BMO Capital | $6 → $9 | Maintains | Market Perform |
| 04/27/2020 | 10.34% | Credit Suisse | $25 → $19 | Maintains | Outperform |
| 01/16/2020 | -1.28% | Benchmark | → $17 | Initiates Coverage On | → Buy |
| 01/13/2020 | 10.34% | Northland Capital Markets | → $19 | Initiates Coverage On | → Outperform |
| 10/15/2019 | 33.57% | Credit Suisse | $20 → $23 | Maintains | Outperform |
| 10/30/2018 | -29.73% | Societe Generale | → $12.1 | Upgrades | Hold → Buy |
| 10/26/2018 | -36.12% | BMO Capital | $14 → $11 | Maintains | Market Perform |
| 08/01/2018 | -7.08% | Morgan Stanley | $15 → $16 | Maintains | Overweight |
| 07/25/2018 | -12.89% | BMO Capital | $14 → $15 | Maintains | Market Perform |
| 07/16/2018 | -18.7% | Jefferies | → $14 | Initiates Coverage On | → Buy |
What is the target price for Constellium (CSTM)?
The latest price target for Constellium (NYSE: CSTM) was reported by Benchmark on July 12, 2023. The analyst firm set a price target for $19.00 expecting CSTM to rise to within 12 months (a possible 10.34% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Constellium (CSTM)?
The latest analyst rating for Constellium (NYSE: CSTM) was provided by Benchmark, and Constellium reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Constellium (CSTM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Constellium, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Constellium was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
Is the Analyst Rating Constellium (CSTM) correct?
While ratings are subjective and will change, the latest Constellium (CSTM) rating was a reiterated with a price target of $0.00 to $19.00. The current price Constellium (CSTM) is trading at is $17.22, which is within the analyst's predicted range.